
Claire Li
Counsel · Fangda Partners · Beijing
Expertise
- Industries
- Life sciences and healthcare
- Energy and natural resources
- Technology, media and telecom
- Manufacturing
- Automotive
- Consumer and retail
- Financial services
- Matters involving
- Germany
- Southeast Asia
- Europe
- Middle East
- Africa
- Central Asia
- Foreign languages
- English
- German
Representative matters
M&A
- Represented Sino Biopharmaceutical in its acquisition of 100% equity interests in Hygieia
- Represented TCL CSOT in its CNY 13.703 billion acquisition of LG Display’s core LCD business in China
- Represented TCL business units in Maxeon Solar Technologies’ global restructuring, which spanned over 30 jurisdictions and involved multiple acquisitions and divestitures
- Represented Luxshare Precision (002475.SZ) in its CNY 1.652 billion acquisition of Qorvo’s semiconductor packaging and testing line and in its long-term strategic cooperation agreement with Qorvo
- Represented EF in the restructuring and sale of its global EF Kids & Teens business to Permira
- Represented KPS Capital in its EUR 3.5 billion acquisition of 100% equity interest in Siemens’ electrical motor and large-drive business Innomotics
- Represented KPS Capital in its EUR 1.7 billion acquisition of 100% equity interest in INEOS Composites, a global leader in producing resins and gelcoats
- Represented China Huaneng in its acquisition of multiple photovoltaic power plants from GCL
- Represented Shanghai Electric in the acquisition of multiple photovoltaic power plants
- Represented VNET Group in its acquisition of TenxCloud
- Represented a Chinese company in its proposed sale of its shares in a German listed company to a world-leading automobile manufacturer
Joint Venture, Strategic Cooperation and Outbound Investment
- Represented Alibaba in its formation of an equity joint venture with Accenture to provide SaaS solutions with a special focus on consumer goods and new retail, smart commuting, and digital energy
- Represented Mylan N.V., as its PRC counsel, in forming a new global pharmaceutical company through its combination with Upjohn, the off-patent branded and generic medicines business of Pfizer Inc.
- Represented a global pharmaceutical company in its proposed strategic alliance with a leading pharmaceutical group in China
- Represented various foreign companies in forming joint ventures in China with their Chinese partners
- Represented multiple Chinese companies in their outbound investments in Central Asia, Southeast Asia, Africa, Europe, the Middle East and other regions
Private Equity & Venture Capital
- Represented CDH, AEP, KKR, Boyu Capital, Hillhouse Capital, CICC Capital, Guanghua Wutong, Jinyi Capital, Temasek and other private equity funds and venture capital in their investments in various portfolio companies
- Represented Didi, Sunshine Insurance, Ping An Insurance and other companies in their equity investments in various start-up companies
- Represented Sina, Unogen and other companies in their early-stage equity financings
Background
Professional experience
- 2018 –
Fangda
- Claire joined Fangda in 2018. Before joining the firm, she worked at a renowned law form in Frankfurt, Germany.
Education
- Southwest University of Political Science and Law
- LL.B.
- Tsinghua University
- LL.M.
- University of Freiburg
- Dr. iur. (Doctor of Law)
Qualifications
- Admitted to practice in the PRC · PRC
Writing & activities
Publications
- Die Veräußerung von GmbH-Geschäftsanteilen an Dritte: Eine rechtsvergleichende Untersuchung zwischen dem deutschen und dem chinesischen Recht